ArticleHRB open research2026
The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol.
Article in HRB open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol.HRB open research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Discontinuation of psychotropic medication is associated with considerable clinical challenges, including withdrawal symptoms and relapse. Pharmacogenomic testing is increasingly used in clinical practice to optimise pharmacotherapy by guiding drug selection and dosing, however, its role in informing medication discontinuation and tapering strategies remains underexplored. Understanding the influence of genetic variability on withdrawal symptoms could support safer, individualised discontinuation practices. Objective: This scoping review aims to map the available evidence on the role of pharmacogenomics on the discontinuation of psychotropic medications. Methods: The review will be conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews and reported using the PRISMA-ScR checklist. Comprehensive searches will be performed in MEDLINE, EMBASE, CINAHL, Web of Science, and PsycINFO. Studies exploring gene polymorphisms relevant to the discontinuation of psychotropic medications (antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, stimulants, and opioids) will be considered. Following screening, data will be extracted, and a narrative synthesis will be undertaken to map characteristics of included studies, genes studied, medication classes involved, reported outcomes, and knowledge gaps. Conclusion: This review will provide an overview of existing evidence and identify gaps regarding the role of pharmacogenomics in psychotropic medication discontinuation. The findings will help to inform future research on the integration of pharmacogenomics into individualised tapering strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.